Cross-Sectional (n=63,624)
A significant proportion of high-risk patients are statin intolerant, and their management varies widely, highlighting the need for clinical trials to determine optimal alternative lipid-lowering strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jose et al. (2013) conducted a cross-sectional in High-risk indication for statin therapy (CAD, atherosclerotic disease, or diabetes) (n=63,624). Statin intolerance vs. Statin tolerance was evaluated on Use of alternative lipid-lowering medications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: